Analysts Anticipate ADMA Biologics Inc (ADMA) Will Post Quarterly Sales of $6.68 Million

Equities research analysts expect ADMA Biologics Inc (NASDAQ:ADMA) to announce $6.68 million in sales for the current quarter, Zacks Investment Research reports. Two analysts have issued estimates for ADMA Biologics’ earnings, with the highest sales estimate coming in at $7.85 million and the lowest estimate coming in at $5.50 million. ADMA Biologics reported sales of $3.33 million during the same quarter last year, which indicates a positive year-over-year growth rate of 100.6%. The company is scheduled to announce its next earnings results on Friday, February 23rd.

According to Zacks, analysts expect that ADMA Biologics will report full year sales of $6.68 million for the current financial year, with estimates ranging from $16.30 million to $18.61 million. For the next fiscal year, analysts anticipate that the business will report sales of $38.15 million per share, with estimates ranging from $28.31 million to $48.00 million. Zacks’ sales calculations are an average based on a survey of research analysts that that provide coverage for ADMA Biologics.

ADMA has been the subject of several research analyst reports. Maxim Group reissued a “buy” rating and issued a $8.00 price objective (down from $13.00) on shares of ADMA Biologics in a research report on Monday, December 11th. Raymond James Financial raised ADMA Biologics from a “market perform” rating to an “outperform” rating and set a $5.00 price objective for the company in a research report on Tuesday, November 14th.

In other ADMA Biologics news, insider Adam S. Grossman acquired 485,000 shares of the stock in a transaction dated Thursday, November 9th. The stock was purchased at an average cost of $2.15 per share, with a total value of $1,042,750.00. The acquisition was disclosed in a document filed with the SEC, which is available at this link. Also, Director Eric I. Richman acquired 25,000 shares of the stock in a transaction dated Thursday, November 9th. The stock was acquired at an average cost of $2.15 per share, with a total value of $53,750.00. Following the completion of the transaction, the director now owns 31,300 shares in the company, valued at approximately $67,295. The disclosure for this purchase can be found here. Over the last three months, insiders bought 526,500 shares of company stock valued at $1,131,975. Corporate insiders own 60.44% of the company’s stock.

A hedge fund recently raised its stake in ADMA Biologics stock. Iguana Healthcare Management LLC boosted its position in ADMA Biologics Inc (NASDAQ:ADMA) by 276.7% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 565,000 shares of the biotechnology company’s stock after buying an additional 415,000 shares during the period. Iguana Healthcare Management LLC owned approximately 2.19% of ADMA Biologics worth $1,740,000 at the end of the most recent quarter. Institutional investors and hedge funds own 32.78% of the company’s stock.

ADMA Biologics (NASDAQ:ADMA) opened at $3.23 on Monday. ADMA Biologics has a 12-month low of $2.01 and a 12-month high of $5.79. The company has a current ratio of 2.36, a quick ratio of 1.35 and a debt-to-equity ratio of 2.26. The stock has a market capitalization of $84.09, a price-to-earnings ratio of -1.62 and a beta of 2.09.

COPYRIGHT VIOLATION NOTICE: This news story was first posted by Community Financial News and is owned by of Community Financial News. If you are reading this news story on another site, it was illegally stolen and reposted in violation of United States and international copyright laws. The legal version of this news story can be read at https://www.com-unik.info/2018/01/08/analysts-anticipate-adma-biologics-inc-adma-will-post-quarterly-sales-of-6-68-million.html.

About ADMA Biologics

ADMA Biologics, Inc is a late-stage biopharmaceutical company that develops, manufactures and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The Company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics.

Get a free copy of the Zacks research report on ADMA Biologics (ADMA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

What are top analysts saying about ADMA Biologics? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for ADMA Biologics and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit